QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Erba, Harry P.
- Patkowska, Elzbieta
- Cortes, Jorge
- Perl, Alexander E.
- Sekeres, Mikkael A.
- Dombret, Herve
- Amadori, Sergio
- Wang, Jianxiang
- Levis, Mark J.
- Schlenk, Richard F.
- Liu, Li
- Kamel, Yasser Mostafa
- Imadalou, Karima
- Laadem, Abderrahmane
- Lesegretain, Arnaud
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Keywords
- AML; clinical trial; FLT3-ITD; quizartinib; age; phase 3
Campos de Estudio
Cita
Erba,HP,Patkowska,E,Cortes,J,Perl,AE,Sekeres,MA,Dombret,H,Amadori,S et al. QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (<i>FLT3</i>-ITD+) Acute Myeloid Leukemia (AML). 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931:CIG MEDIA GROUP, LP. 2024 p.p. 299-299.
Portal de investigación